Dexcom Inc. (NSDQ:DXCM) is launching upgrades for its G6 diabetes system and plans to launch its direct-to-Apple Watch version over the next year.
The Apple and Dexcom collaboration would allow diabetes patients to track glucose through the Apple Watch, a consumer wearable, according to CNBC.
“It’s coming,” Dexcom CEO Kevin Sayer told the network. “And this tool is great for people with diabetes.”
Dexcom’s G6 continuous glucose monitoring system is designed for people with diabetes ages two and up. The device includes a transmitter and a sensor with an auto-applicator. A touchscreen receiver is also available. The G6 eliminates the need for finger sticks and the glucose readings are sent to any Bluetooth-enabled smart device.
“It takes a CGM and makes it much smaller,” Sayer said. “It really will be a device, we think, for the ages and a platform forever. It’s going to be wonderful.”
Dexcom partnered with UnitedHealth in November 2017 to test the CGM and is partnering with Walgreens and CVS in the future.
“We want to be where our patients want to be met, not in our plant or not someplace else,” Sayer said. “[We want to] get the product to the patient where they can use it.”
Dexcom won Health Canada approval for its G6 device earlier this year and plans to commercially launch later in 2019. With more than 8 million people in the U.S. and Europe on insulin therapy, the company wants to launch the G6 system in the Medicare market.
“I assure you there is plenty of room for us to grow over the long term,” Sayer said.
